PO:10:149 | Efficacy of anifrolumab in a case of systemic lupus erythematosus with pulmonary involvement
Background. Pulmonary involvement in systemic lupus erythematosus (SLE) is a heterogeneous and usually non-severe complication, affecting 50–70% of patients (and up to 4–5% at disease onset). Pleuro-parenchymal manifestations include pleuritis (30%), interstitial lung disease (ILD, 1–15%), and lupu...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
PAGEPress Publications
2025-11-01
|
| Col·lecció: | Reumatismo |
| Matèries: | |
| Accés en línia: | https://www.reumatismo.org/reuma/article/view/2146 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|